These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 21242742

  • 21. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B.
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K, Wajgt A, Kondera-Anasz Z.
    Med Sci Monit; 2001 Apr; 7(1):93-8. PubMed ID: 11208501
    [Abstract] [Full Text] [Related]

  • 25. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 26. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
    Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E.
    Acta Neurol Scand; 2010 Dec 01; 122(6):409-13. PubMed ID: 20175758
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr 01; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

  • 37. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C, Ruggieri S.
    Expert Opin Emerg Drugs; 2011 Dec 01; 16(4):697-712. PubMed ID: 22148963
    [Abstract] [Full Text] [Related]

  • 38. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R, Testa G, Assogna F, De Stefano N.
    CNS Drugs; 2024 Apr 01; 38(4):267-279. PubMed ID: 38489020
    [Abstract] [Full Text] [Related]

  • 39. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
    Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A.
    Clin Pharmacokinet; 2019 Mar 01; 58(3):283-297. PubMed ID: 29987837
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.